Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)

Withdrawn before enrolling · Phase 3

Conditions studied: Depression, Anxiety, Externalizing Symptoms, Substance Abuse

In brief

In this 5-year, two-site randomized clinical trial, we propose to test the efficacy of the CATCH-IT primary care/Internet based depression prevention intervention against Attention Monitoring Psychoeducation (AMPE) in preventing the onset of depressive episodes in an intermediate to high risk group of adolescents aged 13-17. We plan to (a) identify high risk adolescents based on elevated scores on the PHQ-A, a screening measure of depressive symptoms; (b) recruit 400 (200 per site) of these at-risk adolescents to be randomized into either the CATCH-IT or the AMPE group; (c) assess outcomes at 2, 8, 12, 18, and 24 months post intake on measures of depressive symptoms, depressive diagnoses, other mental disorders, and on measures of role impairment in education, quality of life, attainment of educational milestones, and family functioning; and (d) conduct exploratory analyses to examine the effectiveness of this intervention program, moderators of protection, and potential ethnic and cultural differences in intervention response.

Key facts

Study ID

NCT01228890

Run by

University of Chicago

People needed

0

Starts

2010-09-01

Expected to finish

2011-04-01

Last updated by the study team

2012-12-17

Who can join

Age: 13 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Youth ages 13 through 17.
• Youth must be experiencing elevated level of depressive symptoms on the Center for Epidemiologic Studies Depression46 (CES-D) scale (score >/= 16) and have at least two core symptoms of Major Depression on the Patient Health Questionnaire, Adolescents.
• Youth will be included if they have a past history of depression, anxiety, externalizing symptoms, or substance abuse.

You may not qualify if…

• Current DSM-IV diagnosis (Kiddie Schedule of Affective Disorders) of Major Depressive Disorder, current therapy for depression, or be taking antidepressants (e.g., SSRIs, TCAs, MAOIs, bupropion, nefazodone, mirtazapine, venlafaxine).
• Current CES-D score >35
• DSM-IV diagnosis of schizophrenia (current or past) or bipolar affective disorder
• Current serious medical illness that causes significant disability or dysfunction
• Significant reading impairment (a minimum sixth-grade reading level based on parental report), mental retardation, or developmental disabilities
• Serious imminent suicidal risk (as determined by endorsement of current suicidality on CES-D or in KSADS interview) or other conditions that may require immediate psychiatric hospitalization
• Psychotic features or disorders, or currently be receiving psychotropic medication
• Extreme, current drug/alcohol abuse (greater than or equal to 2 on the CRAFFT).

Where it is running

• University of Chicago — Chicago, Illinois, United States
• Access Community Health Network — Chicago, Illinois, United States
• Northshore University Health Systems — Evanston, Illinois, United States
• Harvard Vanguard Medical Associates — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.